NAMS CSO Sold $3.4M Before Phase 3 Data Readout

NEW YORK, September 9, The more telling figure at NewAmsterdam Pharma Company N.V. (NAMS) is not the chief scientific officer's $3.36 million exit last month, it is that insiders held only 0.9% of shares outstanding before that sale, while short sellers now control 12.4% of the float. When the people closest to Obicetrapib's clinical prospects own almost none of it and a substantial minority of the market is betting against it, the ESC 2026 Phase 3 readout is not a routine catalyst: it is a verdict on a structurally divided book.

Johannes Kastelein, NAMS's Chief Scientific Officer, sold 125,000 shares at $26.91 on August 24, collecting $3.36 million per SEC Form 4 filings, a timing that placed the transaction immediately ahead of the company's Phase 3 Obicetrapib data presentation at the European Society of Cardiology 2026 congress. The stock has since slipped to $25.63, below his exit price.

Two Constituencies, One Catalyst

The 12.4% short interest and 0.9% insider ownership do not merely coexist, they describe two groups with asymmetric access to clinical evidence reaching opposite conclusions about the same ESC readout. Short interest at that level implies more than routine skepticism; it represents a funded position that requires a specific outcome to unwind. Insider ownership at 0.9%, thin before Kastelein's August transaction, reflects a founding and management team that has not meaningfully accumulated exposure at prices below the analyst consensus. Institutional ownership of 105.7% of shares outstanding, inflated by short-selling mechanics, suggests the borrow is in demand, another expression of the same skeptical trade.

Analysts disagree. The consensus target of $51.58 implies 101% upside from $25.63, a bull case that runs directly through Phase 3 success. That target sits alongside three EPS misses in the last four quarters, including two exceeding 46%, which frames how far current execution is from the scenario the target requires.

The Balance Sheet Is Not the Question

NewAmsterdam Pharma Company N.V. is a late-stage cardiovascular biotech with roughly 100 employees and one lead asset: Obicetrapib, an oral CETP inhibitor in Phase 3 for LDL-C lowering, with a Phase 2a Alzheimer's extension as a second potential indication. The balance sheet is the company's clearest strength, $630 million in cash, zero debt, providing runway at a $143 million annual operating cash burn. Free cash flow ran at -$45 million over the trailing twelve months. A company with this balance sheet does not fail for liquidity reasons; it fails or succeeds on Phase 3 data.

What ESC Resolves

The ESC 2026 congress is the fulcrum. If Phase 3 Obicetrapib data shows clinically significant LDL-C reduction with a clean safety profile, the $51.58 analyst consensus finds its foundation, and the elevated short position begins to unwind, the specific number that would prove the bear case wrong is meaningful LDL-C reduction with no disqualifying safety signal at ESC 2026. If the data disappoints or raises safety concerns, the CSO's August exit at $26.91, above the current $25.63, looks prescient, the 12.4% short position is validated, and thin insider ownership at 0.9% becomes the tell it may already be.

Run the free NewAmsterdam Pharma Company N.V. deep-dive to track the fundamentals heading into the ESC window.

Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.

Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.